Journal article · 2026 · Open access
Targeted intestinal barrier repair via probiotic-derived engineered outer membrane vesicles: A 3A1M strategy with antioxidant, anti-inflammatory, anti-ferroptotic, and microbiome modulation effects
Acta Pharmaceutica Sinica B, 16(4), 2527–2552 · Published 28 January 2026 · DOI 10.1016/j.apsb.2026.01.031
In brief
“Targeted intestinal barrier repair via probiotic-derived engineered outer membrane vesicles: A 3A1M strategy with antioxidant, anti-inflammatory, anti-ferroptotic, and microbiome modulation effects” is a 2026 journal article by Yu Li and 16 co-authors, published in Acta Pharmaceutica Sinica B. OpenAlex counts 31 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Acta Pharmaceutica Sinica B.
- Citations
- 31
- Most cited in
- 2026 (31)
- Field-weighted impact
- 110.88
- References
- 93
- Authors
- 17
Abstract
Intestinal barrier disruption, driven by oxidative stress, ferroptosis, immune imbalance, and gut microbiota dysbiosis, plays a crucial role in inflammatory bowel disease (IBD) pathogenesis. Current treatments are often ineffective and cause side effects, emphasizing the need for novel therapies. Here, we have developed an engineered probiotic-derived outer membrane vesicle (OMV), GDO@CM, combining antioxidant gallic acid (GA) and anti-inflammatory H 2 S for targeted intestinal barrier repair. Constructed from Escherichia coli Nissle 1917 (EcN)-derived OMVs, GA and DATS are incorporated into the hydrophilic inner cavity and lipid bilayer, respectively, while mannose-decorated chitosan (CM) is electrostatically attached to the OMVs surface, enhancing stability and enabling targeted delivery to damaged colonic lesions. GDO@CM efficiently enters activated immune cells and epithelial cells, where GA scavenges reactive oxygen species and inhibits ferroptosis, while H 2 S amplifies anti-inflammatory effects. OMVs further synergize with GA and DATS to suppress pathogenic bacteria. These combined actions facilitate effective barrier repair and alleviate IBD symptoms. Single-cell RNA sequencing reveals that GDO@CM reduces inflammation, increases the proportion of reparative M2 macrophages and intestinal stem cells, and promotes epithelial cell proliferation via the APP/CD74 axis. Our findings establish GDO@CM as a promising multi-target therapeutic for IBD, offering a novel strategy for intestinal barrier restoration. Engineered OMVs-based nanoplatform GDO@CM delivers antioxidant gallic acid and anti-inflammatory H 2 S to effectively restore intestinal barrier integrity, modulate immunity, inhibit ferroptosis, and rebalance gut microbiota, thereby alleviating inflammatory bowel disease.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Li, Y., Zhang, H., Shi, C., Zhou, Q., Li, J., Lu, B., Lu, H., Jin, T., Zhu, Y., Zuo, T., Xu, M., Su, M., Zhang, Y., Shubhra, Q. T., Hu, X., Deng, H., & Cai, X. (2026). Targeted intestinal barrier repair via probiotic-derived engineered outer membrane vesicles: A 3A1M strategy with antioxidant, anti-inflammatory, anti-ferroptotic, and microbiome modulation effects. Acta Pharmaceutica Sinica B, 16(4), 2527–2552. https://doi.org/10.1016/j.apsb.2026.01.031
MLA 9
Li, Yu, et al. “Targeted intestinal barrier repair via probiotic-derived engineered outer membrane vesicles: A 3A1M strategy with antioxidant, anti-inflammatory, anti-ferroptotic, and microbiome modulation effects.” Acta Pharmaceutica Sinica B, vol. 16, no. 4, 2026, pp. 2527–2552. https://doi.org/10.1016/j.apsb.2026.01.031.
Chicago
Li, Yu, He Zhang, Chengge Shi, Qiang Zhou, Jiayu Li, Bin Lu, Hongyang Lu, et al. 2026. “Targeted intestinal barrier repair via probiotic-derived engineered outer membrane vesicles: A 3A1M strategy with antioxidant, anti-inflammatory, anti-ferroptotic, and microbiome modulation effects.” Acta Pharmaceutica Sinica B 16 (4): 2527–2552. https://doi.org/10.1016/j.apsb.2026.01.031.
Harvard
Li, Y. et al. (2026) ‘Targeted intestinal barrier repair via probiotic-derived engineered outer membrane vesicles: A 3A1M strategy with antioxidant, anti-inflammatory, anti-ferroptotic, and microbiome modulation effects’, Acta Pharmaceutica Sinica B, 16(4), pp. 2527–2552. doi:10.1016/j.apsb.2026.01.031.
IEEE
Y. Li et al., “Targeted intestinal barrier repair via probiotic-derived engineered outer membrane vesicles: A 3A1M strategy with antioxidant, anti-inflammatory, anti-ferroptotic, and microbiome modulation effects,” Acta Pharmaceutica Sinica B, vol. 16, no. 4, pp. 2527–2552, 2026, doi: 10.1016/j.apsb.2026.01.031.
BibTeX
@article{li2026targeted,
title = {{Targeted intestinal barrier repair via probiotic-derived engineered outer membrane vesicles: A 3A1M strategy with antioxidant, anti-inflammatory, anti-ferroptotic, and microbiome modulation effects}},
author = {Li, Yu and Zhang, He and Shi, Chengge and Zhou, Qiang and Li, Jiayu and Lu, Bin and Lu, Hongyang and Jin, Ting and Zhu, Yinci and Zuo, Tianci and Xu, Mengzhu and Su, Mingli and Zhang, Yanmei and Shubhra, Quazi T.H. and Hu, Xiaowen and Deng, Hui and Cai, Xiaojun},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
volume = {16},
number = {4},
pages = {2527--2552},
doi = {10.1016/j.apsb.2026.01.031},
url = {https://doi.org/10.1016/j.apsb.2026.01.031}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Escherichia coli Nissle 1917
- intestinal barrier repair
- inflammatory bowel disease
- gallic acid
- hydrogen sulfide
- targeted delivery
- ferroptosis
- oxidative stress
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Li, Y., Zhang, H., Shi, C., Zhou, Q., Li, J., Lu, B., Lu, H., Jin, T., Zhu, Y., Zuo, T., Xu, M., Su, M., Zhang, Y., Shubhra, Q. T., Hu, X., Deng, H., & Cai, X. (2026). Targeted intestinal barrier repair via probiotic-derived engineered outer membrane vesicles: A 3A1M strategy with antioxidant, anti-inflammatory, anti-ferroptotic, and microbiome modulation effects. Acta Pharmaceutica Sinica B, 16(4), 2527–2552. https://doi.org/10.1016/j.apsb.2026.01.031
How many times has this paper been cited?
31 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Acta Pharmaceutica Sinica B: sign in and open the full text from this page.
Who wrote this paper?
Yu Li, He Zhang, Chengge Shi, Qiang Zhou, Jiayu Li, Bin Lu, Hongyang Lu, Ting Jin, Yinci Zhu, Tianci Zuo, Mengzhu Xu, Mingli Su and 5 more.
What is the DOI of this paper?
10.1016/j.apsb.2026.01.031, permanently at https://doi.org/10.1016/j.apsb.2026.01.031. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.